BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35316518)

  • 21. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
    Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
    AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
    Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
    Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation between glioblastomas and brain metastases and regarding their primary site of malignancy using dynamic susceptibility contrast MRI at 3T.
    Askaner K; Rydelius A; Engelholm S; Knutsson L; Lätt J; Abul-Kasim K; Sundgren PC
    J Neuroradiol; 2019 Nov; 46(6):367-372. PubMed ID: 30389510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accuracy of apparent diffusion coefficients and enhancement ratios on magnetic resonance imaging in differentiating primary cerebral lymphomas from glioblastoma.
    Anwar SSM; Baig MZ; Laghari AA; Mubarak F; Shamim MS; Jilani UA; Khalid MU
    Neuroradiol J; 2019 Oct; 32(5):328-334. PubMed ID: 31188064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiating brain metastasis from glioblastoma by time-dependent diffusion MRI.
    Kamimura K; Kamimura Y; Nakano T; Hasegawa T; Nakajo M; Yamada C; Akune K; Ejima F; Ayukawa T; Ito S; Nagano H; Takumi K; Nakajo M; Uchida H; Tabata K; Iwanaga T; Imai H; Feiweier T; Yoshiura T
    Cancer Imaging; 2023 Aug; 23(1):75. PubMed ID: 37553578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of the apparent diffusion coefficient for the evaluation of the white matter to differentiate between glioblastoma and brain metastases.
    Miquelini LA; Pérez Akly MS; Funes JA; Besada CH
    Radiologia; 2016; 58(3):207-13. PubMed ID: 26655126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of apparent diffusion coefficient in differentiating between high-grade gliomas and brain metastases.
    Caravan I; Ciortea CA; Contis A; Lebovici A
    Acta Radiol; 2018 May; 59(5):599-605. PubMed ID: 28835111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Value of Minimum Apparent Diffusion Coefficient in Peritumoral Edema in the Differential Diagnosis between Primary Central Nervous System Lymphoma and Glioblastoma].
    Li MG; Chen ZY; Liu G; Xiao HF; Chen XJ; Lou X; Ma L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Apr; 40(2):146-150. PubMed ID: 29724302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multimodal MR Features of 8 Cases of Epithelioid Glioblastoma.
    Zhao JP; Cui CX; Wang JC; Su HW; Duan CF; Liu XJ
    Biomed Res Int; 2020; 2020():9586806. PubMed ID: 33123592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions.
    Sundgren PC; Fan X; Weybright P; Welsh RC; Carlos RC; Petrou M; McKeever PE; Chenevert TL
    Magn Reson Imaging; 2006 Nov; 24(9):1131-42. PubMed ID: 17071335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results.
    Di Costanzo A; Trojsi F; Giannatempo GM; Vuolo L; Popolizio T; Catapano D; Bonavita S; d'Angelo VA; Tedeschi G; Scarabino T
    J Exp Clin Cancer Res; 2006 Sep; 25(3):383-90. PubMed ID: 17167979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma.
    Stecco A; Pisani C; Quarta R; Brambilla M; Masini L; Beldì D; Zizzari S; Fossaceca R; Krengli M; Carriero A
    J Neurooncol; 2011 Apr; 102(2):261-71. PubMed ID: 20658351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma.
    Cindil E; Sendur HN; Cerit MN; Dag N; Erdogan N; Celebi FE; Oner Y; Tali T
    Neuroradiology; 2021 Mar; 63(3):331-342. PubMed ID: 32821962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
    Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
    J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
    Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
    Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility-weighted imaging provides complementary value to diffusion-weighted imaging in the differentiation between pyogenic brain abscesses, necrotic glioblastomas, and necrotic metastatic brain tumors.
    Lai PH; Chung HW; Chang HC; Fu JH; Wang PC; Hsu SH; Hsu SS; Lin HS; Chuang TC
    Eur J Radiol; 2019 Aug; 117():56-61. PubMed ID: 31307653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.